WASHINGTON, April 11 (Reuters) – AbbVie Inc won U.S. regulatory approval on Monday for a new drug to treat patients with a rare type of chronic lymphocytic leukemia, a blood cancer.
The post UPDATE 1-AbbVie/Roche drug gets U.S. approval for a rare type of leukemia appeared first on NASDAQ.